Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Journal for ImmunoTherapy of Cancer

Volumn 6, Issue 1, 2018, Pages

  Abu Sbeih, Hamzah ^a   Ali, Faisal S ^a   Luo, Wenyi ^a   Qiao, Wei ^a   Raju, Gottumukkala S ^a   Wang, Yinghong ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Colitis; Diarrhea; Endoscopy; Histology; Immune checkpoint inhibitors

Indexed keywords

CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; VEDOLIZUMAB; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; COLITIS; COLON PERFORATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; ENDOSCOPIC BIOPSY; ENDOSCOPY; FEMALE; HEMODYNAMICS; HISTOLOGY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT DURATION; AGED; BIOPSY; COMORBIDITY; COMPLICATION; DISEASE MANAGEMENT; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; ODDS RATIO; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS; BIOPSY; COLITIS; COMORBIDITY; DISEASE MANAGEMENT; ENDOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 85054012525     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-018-0411-1     Document Type: Article

References (23)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
2. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558-68.
3. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345-56.
4. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving Nivolumab. J Clin Oncol. 2015;33(18):2013-20.
5. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-33.
6. Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
7. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48.
8. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl-4):iv119-42.
9. Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6(10):e1344805.
10. Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8):1695-705.
11. Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO open. 2018;3(1):e000278.
12. Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of Ipilimumab-associated colitis. Clin Gastroenterol Hepatol. 2016;14(6):836-42.
13. Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol. 2017;8:1547.
14. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Oncol Pract. 2018;36(17):1714-68.
15. Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer immunology, immunotherapy: CII. 2017;66(5):581-92.
16. Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ case reports. 2016;2016. PMID: 27539137
17. Wang Y, Pei F, Wang X, Sun Z, Hu C, Dou H. Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis. Int J Clin Exp Pathol. 2015;8(10):12319-32.
18. Sands BE, Panés J, Higgins PDR, et al. Post-hoc analysis of Tofacitinib Crohn's disease phase 2 induction efficacy in subgroups with baseline endoscopic or biomarker evidence of inflammation. Gastroentrology. 2017;154(1):S81.
19. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54(11):2538-40.
20. Linardou H, Gogas H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med. 2016;4(14):272.
21. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (London, England). 2008;371(9613):660-7.
22. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383-95.
23. Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6(1):37.